Pricing Log in Create free account

Bright Minds Biosciences Inc. (DRUG) vs Inhibikase Therapeutics, Inc. (IKT)

Bright Minds Biosciences Inc. and Inhibikase Therapeutics, Inc. are both Biotechnology companies. Bright Minds Biosciences Inc. and Inhibikase Therapeutics, Inc. are of similar size ($226.9M and $209.3M). Across the 9 metrics below, Bright Minds Biosciences Inc. leads on 6 and Inhibikase Therapeutics, Inc. on 3.

Valuation

Metric DRUG IKT Biotechnology median
P/E n/m n/m 10.60
P/S n/m 1,005.21 9.40
P/B 1.02 1.71 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m 394.78 9.02
Earnings yield (9.04%) (28.67%) (32.88%)
Free cash flow yield (7.85%) (16.28%) (23.13%)

Profitability

Metric DRUG IKT Biotechnology median
Gross margin 0.00% 100.00% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (13.64%) (51.96%) (51.96%)
Return on assets (13.52%) (48.04%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric DRUG IKT Biotechnology median
Revenue growth (TTM) — 110.93% 6.76%
EPS growth (last fiscal year) (164.58%) 57.76% 29.88%
Revenue growth, 5-year CAGR — (42.21%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric DRUG IKT Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 121.98 15.82 4.97
Net debt to EBITDA 5.98 3.44 1.01

Dividend

Metric DRUG IKT Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric DRUG IKT Biotechnology median
Market cap 226.87m 209.30m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack